DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

書誌詳細
主要な著者:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
フォーマット:	Journal article
言語:	English
出版事項:	Oxford University Press 2014

類似資料

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
著者:: Gupta, A, 等
出版事項: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
著者:: Gupta, A, 等
出版事項: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
著者:: Robert, C, 等
出版事項: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
著者:: Robert, C, 等
出版事項: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
著者:: Kirkwood, J, 等
出版事項: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
著者:: Flaherty, K, 等
出版事項: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
著者:: K. Haslett, 等
出版事項: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
著者:: Edmund Poon, 等
出版事項: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
著者:: Jessie Villanueva, 等
出版事項: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
著者:: Paolo A. Ascierto, 等
出版事項: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
著者:: Eva Marie Erfurth, 等
出版事項: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
著者:: Andrea Gazzin, 等
出版事項: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
著者:: Tahar Sif eddine Bouchema, 等
出版事項: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
著者:: Pacey, S, 等
出版事項: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
著者:: Anne L Estep, 等
出版事項: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
著者:: Sara Bjursten, 等
出版事項: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
著者:: Sarah J. Welsh, 等
出版事項: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
著者:: Blessie Elizabeth Nelson, 等
出版事項: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
著者:: Sarit Cohen‐Rabbie, 等
出版事項: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
著者:: Hui-Ju Huang, 等
出版事項: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
著者:: Leijen, S, 等
出版事項: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
著者:: Leijen, S, 等
出版事項: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
著者:: Bengt Tholander, 等
出版事項: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
著者:: Ken Saijo, 等
出版事項: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
著者:: Anaïs Roeser, 等
出版事項: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
著者:: Lovisa Falkman, 等
出版事項: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
著者:: Clare Judith Stones, 等
出版事項: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
著者:: Jan Leipe, 等
出版事項: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
著者:: Matthew R. Kroll, 等
出版事項: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
著者:: Shivshankari Rajkumar, 等
出版事項: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
著者:: J. Steininger, 等
出版事項: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
著者:: I. V. Samoylenko, 等
出版事項: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
著者:: B. Ziółkowska, 等
出版事項: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
著者:: Michael J. Vido, 等
出版事項: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
著者:: Zeynep Eroglu, 等
出版事項: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
著者:: Raphael Reinhard, MD, 等
出版事項: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
著者:: Manrose Singh, 等
出版事項: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
著者:: Sivakamavalli Jeyachandran
出版事項: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
著者:: Ariane Fizazi, 等
出版事項: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
著者:: Marit A. C. Vermunt, 等
出版事項: (2021-08-01)